Jennifer D Brooks

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1232554/publications.pdf

Version: 2024-02-01

48 papers

1,608 citations

20 h-index 39 g-index

50 all docs 50 docs citations

50 times ranked

2142 citing authors

#	Article	IF	CITATIONS
1	Background Parenchymal Enhancement at Breast MR Imaging and Breast Cancer Risk. Radiology, 2011, 260, 50-60.	7.3	292
2	Mammalian lignans and genistein decrease the activities of aromatase and $17\hat{1}^2$ -hydroxysteroid dehydrogenase in MCF-7 cells. Journal of Steroid Biochemistry and Molecular Biology, 2005, 94, 461-467.	2.5	164
3	Breast Cancers Detected at Screening MR Imaging and Mammography in Patients at High Risk: Method of Detection Reflects Tumor Histopathologic Results. Radiology, 2016, 280, 716-722.	7.3	108
4	Impact of menopausal status on background parenchymal enhancement and fibroglandular tissue on breast MRI. European Radiology, 2012, 22, 2641-2647.	4.5	105
5	Risk of Asynchronous Contralateral Breast Cancer in Noncarriers of <i>BRCA1</i> and <i>BRCA2</i> Mutations With a Family History of Breast Cancer: A Report From the Women's Environmental Cancer and Radiation Epidemiology Study. Journal of Clinical Oncology, 2013, 31, 433-439.	1.6	101
6	Impact of Tamoxifen on Amount of Fibroglandular Tissue, Background Parenchymal Enhancement, and Cysts on Breast Magnetic Resonance Imaging. Breast Journal, 2012, 18, 527-534.	1.0	80
7	Effect of Aromatase Inhibitors on Background Parenchymal Enhancement and Amount of Fibroglandular Tissue at Breast MR Imaging. Radiology, 2012, 264, 670-678.	7.3	74
8	Personalized Risk Assessment for Prevention and Early Detection of Breast Cancer: Integration and Implementation (PERSPECTIVE I&I). Journal of Personalized Medicine, 2021, 11, 511.	2.5	59
9	Systemic therapy for breast cancer and risk of subsequent contralateral breast cancer in the WECARE Study. Breast Cancer Research, 2016, 18, 65.	5.0	33
10	Alcohol consumption and cigarette smoking in combination: A predictor of contralateral breast cancer risk in the WECARE study. International Journal of Cancer, 2017, 141, 916-924.	5.1	31
11	Coronary Artery Disease in Young Women After Radiation Therapy for Breast Cancer. JACC: CardioOncology, 2021, 3, 381-392.	4.0	31
12	The association of estimated cardiorespiratory fitness with COVID-19 incidence and mortality: A cohort study. PLoS ONE, 2021, 16, e0250508.	2.5	30
13	Histopathologic characteristics of background parenchymal enhancement (BPE) on breast MRI. Breast Cancer Research and Treatment, 2018, 172, 487-496.	2.5	29
14	Association of Common Genetic Variants With Contralateral Breast Cancer Risk in the WECARE Study. Journal of the National Cancer Institute, 2017, 109, .	6.3	28
15	Women's Views on Multifactorial Breast Cancer Risk Assessment and Risk-Stratified Screening: A Population-Based Survey from Four Provinces in Canada. Journal of Personalized Medicine, 2021, 11, 95.	2.5	28
16	Hormone receptor status of a first primary breast cancer predicts contralateral breast cancer risk in the WECARE study population. Breast Cancer Research, 2017, 19, 83.	5.0	27
17	Analysis of Platelet Count and New Cancer Diagnosis Over a 10-Year Period. JAMA Network Open, 2022, 5, e2141633.	5.9	27
18	The association of mammographic density with risk of contralateral breast cancer and change in density with treatment in the WECARE study. Breast Cancer Research, 2018, 20, 23.	5.0	24

#	Article	IF	CITATIONS
19	Variants in activators and downstream targets of ATM, radiation exposure, and contralateral breast cancer risk in the WECARE study. Human Mutation, 2012, 33, 158-164.	2.5	23
20	MRI background parenchymal enhancement, breast density and serum hormones in postmenopausal women. International Journal of Cancer, 2018, 143, 823-830.	5.1	23
21	Reproductive Status at First Diagnosis Influences Risk of Radiation-Induced Second Primary Contralateral Breast Cancer in the WECARE Study. International Journal of Radiation Oncology Biology Physics, 2012, 84, 917-924.	0.8	22
22	Body mass index, weight change, and risk of second primary breast cancer in the <scp>WECARE</scp> study: influence of estrogen receptor status of the first breast cancer. Cancer Medicine, 2016, 5, 3282-3291.	2.8	22
23	Radiation Treatment, <i>ATM</i> , <i>BRCA1/2</i> , and <i>CHEK2</i> *1100delC Pathogenic Variants and Risk of Contralateral Breast Cancer. Journal of the National Cancer Institute, 2020, 112, 1275-1279.	6.3	21
24	Association between maternal cannabis use and birth outcomes: an observational study. BMC Pregnancy and Childbirth, 2020, 20, 771.	2.4	19
25	Body mass index and risk of second primary breast cancer: The WECARE Study. Breast Cancer Research and Treatment, 2012, 131, 571-580.	2.5	18
26	Reproductive factors, tumor estrogen receptor status and contralateral breast cancer risk: results from the WECARE study. SpringerPlus, 2015, 4, 825.	1.2	18
27	Platelet Count and Survival after Cancers. Cancers, 2022, 14, 549.	3.7	17
28	Identifying Children and Youth With Autism Spectrum Disorder in Electronic Medical Records: Examining Health System Utilization and Comorbidities. Autism Research, 2021, 14, 400-410.	3.8	16
29	Impact of fibroglandular tissue and background parenchymal enhancement on diffusion weighted imaging of breast lesions. European Journal of Radiology, 2014, 83, 2137-2143.	2.6	14
30	Variation in Genes Related to Obesity, Weight, and Weight Change and Risk of Contralateral Breast Cancer in the WECARE Study Population. Cancer Epidemiology Biomarkers and Prevention, 2012, 21, 2261-2267.	2.5	11
31	CYP2D6 phenotype, tamoxifen, and risk of contralateral breast cancer in the WECARE Study. Breast Cancer Research, 2018, 20, 149.	5.0	11
32	Association of breast cancer with MRI background parenchymal enhancement: the IMAGINE case-control study. Breast Cancer Research, 2020, 22, 138.	5.0	10
33	The impact of chronic comorbidities at the time of breast cancer diagnosis on quality of life, and emotional health following treatment in Canada. PLoS ONE, 2021, 16, e0256536.	2.5	10
34	Association between maternal acetaminophen use and adverse birth outcomes in a pregnancy and birth cohort. Pediatric Research, 2020, 87, 1263-1269.	2.3	9
35	Measures of Adiposity and Risk of Testing Positive for SARS-CoV-2 in the UK Biobank Study. Journal of Obesity, 2021, 2021, 1-6.	2.7	9
36	Assessing the validity of administrative health data for the identification of children and youth with autism spectrum disorder in Ontario. Autism Research, 2021, 14, 1037-1045.	3.8	9

#	Article	IF	CITATIONS
37	Should Age-Dependent Absolute Risk Thresholds Be Used for Risk Stratification in Risk-Stratified Breast Cancer Screening?. Journal of Personalized Medicine, 2021, 11, 916.	2.5	8
38	Contraceptive use and the risk of ovarian cancer among women with a BRCA1 or BRCA2 mutation. Gynecologic Oncology, 2022, 164, 514-521.	1.4	8
39	Statistical power in COVID-19 case-control host genomic study design. Genome Medicine, 2020, 12, 115.	8.2	7
40	Common variants in genes coding for chemotherapy metabolizing enzymes, transporters, and targets: a case–control study of contralateral breast cancer risk in the WECARE Study. Cancer Causes and Control, 2013, 24, 1605-1614.	1.8	6
41	Smoking, Radiation Therapy, and Contralateral Breast Cancer Risk in Young Women. Journal of the National Cancer Institute, 2022, 114, 631-634.	6.3	6
42	Association of a Pathway-Specific Genetic Risk Score With Risk of Radiation-Associated Contralateral Breast Cancer. JAMA Network Open, 2019, 2, e1912259.	5.9	5
43	Risk-Stratified Approach to Breast Cancer Screening in Canada: Women's Knowledge of the Legislative Context and Concerns about Discrimination from Genetic and Other Predictive Health Data. Journal of Personalized Medicine, 2021, 11, 726.	2.5	5
44	A case-control study of the joint effect of reproductive factors and radiation treatment for first breast cancer and risk of contralateral breast cancer in the WECARE study. Breast, 2020, 54, 62-69.	2.2	3
45	Association of contralateral breast cancer risk with mammographic density defined at higherâ€thanâ€conventional intensity thresholds. International Journal of Cancer, 2022, 151, 1304-1309.	5.1	3
46	Considerations of Biomarker Application for Cancer Continuum in the Era of Precision Medicine. Current Epidemiology Reports, 2022, 9, 200-211.	2.4	2
47	The association of sex and calendar month with changes in weight: A retrospective cohort study of a community-based weight management clinic. Obesity Research and Clinical Practice, 2021, 15, 515-517.	1.8	1
48	Mammographic texture features associated with contralateral breast cancer in the WECARE Study. Npj Breast Cancer, 2021, 7, 146.	5.2	1